Holen Sie sich die Stockscreener-App
0.56
1.75%
-0.010
Schlusskurs vom Vortag:
$0.57
Offen:
$0.5655
24-Stunden-Volumen:
39,047
Relative Volume:
0.29
Marktkapitalisierung:
$21.87M
Einnahmen:
$7.88M
Nettoeinkommen (Verlust:
$-69.20M
KGV:
-0.2745
EPS:
-2.04
Netto-Cashflow:
$-69.73M
1W Leistung:
-10.03%
1M Leistung:
-12.17%
6M Leistung:
-27.74%
1J Leistung:
-35.26%
1-Tages-Spanne:
$0.5513
$0.585
1-Wochen-Bereich:
$0.54
$0.6224
52-Wochen-Spanne:
$0.54
$1.56
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Firmenname
Bolt Biotherapeutics Inc
Sektor
Branche
Telefon
650-665-9295
Adresse
900 CHESAPEAKE DRIVE, REDWOOD CITY
Vergleichen Sie BOLT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BOLT | 0.56 | 21.87M | 7.88M | -69.20M | -69.73M | -2.04 |
| VRTX | 449.74 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.06 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.25 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.30 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | Eingeleitet | Guggenheim | Buy |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Bolt Biotherapeutics Inc Aktie (BOLT) Neueste Nachrichten
Bolt Biotherapeutics stock hits 52-week low at $0.54 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.54 - Investing.com
HC Wainwright Issues Pessimistic Forecast for BOLT Earnings - Defense World
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look - TipRanks
Bolt Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot - Houston Chronicle
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation - Yahoo Finance
BOLTBolt Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - The Manila Times
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Marketscreener.com
Bolt Biotherapeutics (STU:6LP) Cash Flow from Investing : €52.47 Mil (TTM As of Jun. 2024) - GuruFocus.com
Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
BOLT Stock Surges Over 5% Amidst Biotech Sector's Mixed Performa - GuruFocus.com
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline
Bolt Biotherapeutics (BOLT) Stock Surges Amid Broad Biotech Indu - GuruFocus.com
Renaissance Technologies LLC Sells 240,898 Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World
Renaissance Technologies LLC Has $208,000 Stock Holdings in Hesai Group (NASDAQ:HSAI) - Defense World
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 39.1% - Defense World
Just Auto Excellence Awards 2024: TomTom - just-auto.com
Bolt Biotherapeutics (BOLT) Stock Surges Amid Biotech Sector Vol - GuruFocus.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 14.2% in September - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.61 - Investing.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.65 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.65 - Investing.com
Bolt Biotherapeutics Announces Changes to its Board of Directors - ForexTV.com
Bolt Biotherapeutics reshuffles board, appoints new chair By Investing.com - Investing.com Canada
Bolt Biotherapeutics reshuffles board, appoints new director - Investing.com
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment - TipRanks
Deadline on Sept. 3rd coming up in Lawsuit for Investors in shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) - openPR
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesBOLT - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the - EIN News
BOLT Investors Have the Opportunity to Lead Bolt - GlobeNewswire
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - The Malaysian Reserve
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Finansavisen - Finansavisen
Finanzdaten der Bolt Biotherapeutics Inc-Aktie (BOLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):